Charles Schwab
HUMA icon

Charles Schwab’s Humacyte HUMA Stock Holding History

Charles Schwab’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
1,353,515
+62,170
+5% +$57.6K ﹤0.01% 2992
2026
Q1 		$783K Buy
1,291,345
+51,868
+4% +$53.9K ﹤0.01% 2969
2025
Q4 		$1.19M Buy
1,239,477
+227,560
+22% +$322K ﹤0.01% 2867
2025
Q3 		$1.76M Buy
1,011,917
+90,044
+10% +$176K ﹤0.01% 2782
2025
Q2 		$1.93M Buy
921,873
+156,620
+20% +$301K ﹤0.01% 2680
2025
Q1 		$1.3M Sell
765,253
-10,465
-1% -$39.3K ﹤0.01% 2753
2024
Q4 		$3.92M Buy
775,718
+54,400
+8% +$269K ﹤0.01% 2449
2024
Q3 		$3.92M Buy
721,318
+66,946
+10% +$441K ﹤0.01% 2486
2024
Q2 		$3.14M Buy
654,372
+180,605
+38% +$940K ﹤0.01% 2543
2024
Q1 		$1.47M Sell
473,767
-17,490
-4% -$58.8K ﹤0.01% 2679
2023
Q4 		$1.4M Buy
491,257
+32,794
+7% +$84.2K ﹤0.01% 2721
2023
Q3 		$1.34M Buy
458,463
+58,920
+15% +$195K ﹤0.01% 2704
2023
Q2 		$1.14M Buy
399,543
+3,190
+0.8% +$11.5K ﹤0.01% 2720
2023
Q1 		$1.22M Sell
396,353
-3,831
-1% -$10.9K ﹤0.01% 2674
2022
Q4 		$844K Buy
400,184
+96,460
+32% +$293K ﹤0.01% 2830
2022
Q3 		$991K Sell
303,724
-26,782
-8% -$103K ﹤0.01% 2801
2022
Q2 		$1.06M Buy
330,506
+28,864
+10% +$160K ﹤0.01% 2769
2022
Q1 		$2.13M Buy
301,642
+7,402
+3% +$43.1K ﹤0.01% 2624
2021
Q4 		$2.13M Buy
+294,240
New +$2.91M ﹤0.01% 2690

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's HUMA Position: Q2 2026 in Review

Charles Schwab increased its Humacyte (HUMA) stake by 4.8% in Q2 2026, buying an estimated $57.6K and bringing the position to 1,353,515 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2992.

Charles Schwab first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.92M in Q3 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Charles Schwab held 1,353,515 shares of Humacyte worth $1.06M as of Q2 2026.
  • Charles Schwab bought 62,170 Humacyte shares in Q2 2026, an estimated $57.6K.
  • Humacyte made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2992 holding.
  • Charles Schwab first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
  • Charles Schwab's Humacyte position peaked at $3.92M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.